225 related articles for article (PubMed ID: 9537258)
1. Comparative decreases in tyrosinase, TRP-1, TRP-2, and Pmel 17/silver antigenic proteins from melanotic to amelanotic stages of syngeneic mouse cutaneous melanomas and metastases.
Orlow SJ; Silvers WK; Zhou BK; Mintz B
Cancer Res; 1998 Apr; 58(7):1521-3. PubMed ID: 9537258
[TBL] [Abstract][Full Text] [Related]
2. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ; Kitson JL; Silvers WK; Mintz B
Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
[TBL] [Abstract][Full Text] [Related]
3. Comparison of tyrosinase-related protein-2, S-100, and Melan A immunoreactivity in canine amelanotic melanomas.
Choi C; Kusewitt DF
Vet Pathol; 2003 Nov; 40(6):713-8. PubMed ID: 14608029
[TBL] [Abstract][Full Text] [Related]
4. Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression.
Orlow SJ; Hearing VJ; Sakai C; Urabe K; Zhou BK; Silvers WK; Mintz B
Proc Natl Acad Sci U S A; 1995 Oct; 92(22):10152-6. PubMed ID: 7479744
[TBL] [Abstract][Full Text] [Related]
5. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections.
Kaufmann O; Koch S; Burghardt J; Audring H; Dietel M
Mod Pathol; 1998 Aug; 11(8):740-6. PubMed ID: 9720502
[TBL] [Abstract][Full Text] [Related]
6. Development of cutaneous amelanotic melanoma in the absence of a functional tyrosinase.
Cohen-Solal KA; Reuhl KR; Ryan KB; Roberts KG; Chen S
Pigment Cell Res; 2001 Dec; 14(6):466-74. PubMed ID: 11775059
[TBL] [Abstract][Full Text] [Related]
7. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
[TBL] [Abstract][Full Text] [Related]
8. Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: a projected basis for immunotherapy.
Le Fur N; Kelsall SR; Silvers WK; Mintz B
Proc Natl Acad Sci U S A; 1997 May; 94(10):5332-7. PubMed ID: 9144237
[TBL] [Abstract][Full Text] [Related]
9. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas.
Takeuchi H; Kuo C; Morton DL; Wang HJ; Hoon DS
Cancer Res; 2003 Jan; 63(2):441-8. PubMed ID: 12543800
[TBL] [Abstract][Full Text] [Related]
10. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
[TBL] [Abstract][Full Text] [Related]
11. Cotransfection of genes encoding human tyrosinase and tyrosinase-related protein-1 prevents melanocyte death and enhances melanin pigmentation and gene expression of Lamp-1.
Luo D; Chen H; Jimbow K
Exp Cell Res; 1994 Jul; 213(1):231-41. PubMed ID: 8020595
[TBL] [Abstract][Full Text] [Related]
12. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.
Chi DD; Merchant RE; Rand R; Conrad AJ; Garrison D; Turner R; Morton DL; Hoon DS
Am J Pathol; 1997 Jun; 150(6):2143-52. PubMed ID: 9176405
[TBL] [Abstract][Full Text] [Related]
13. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
14. Ultraviolet radiation-induced malignant skin melanoma in melanoma-susceptible transgenic mice.
Klein-Szanto AJ; Silvers WK; Mintz B
Cancer Res; 1994 Sep; 54(17):4569-72. PubMed ID: 8062242
[TBL] [Abstract][Full Text] [Related]
15. Improvement of the tumor-suppressive effect of boron neutron capture therapy for amelanotic melanoma by intratumoral injection of the tyrosinase gene.
Morita N; Hiratsuka J; Kondoh H; Uno M; Asano T; Niki Y; Sakurai Y; Ono K; Harada T; Imajo Y
Cancer Res; 2006 Apr; 66(7):3747-53. PubMed ID: 16585201
[TBL] [Abstract][Full Text] [Related]
16. Value of dopachrome tautomerase detection in the assessment of melanocytic tumors.
Filimon A; Zurac SA; Milac AL; Sima LE; Petrescu SM; Negroiu G
Melanoma Res; 2014 Jun; 24(3):219-36. PubMed ID: 24709887
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tyrosinase levels in amelanotic and melanotic melanoma cell cultures by a competitive enzyme-linked immunoadsorbent assay and by immunotitration analysis.
Fuller BB; Iman DS; Lunsford JB
J Cell Physiol; 1988 Jan; 134(1):149-54. PubMed ID: 3121644
[TBL] [Abstract][Full Text] [Related]
18. Progressive appearance of pigmentation in amelanotic melanoma lesions.
Cohen-Solal KA; Crespo-Carbone SM; Namkoong J; Mackason KR; Roberts KG; Reuhl KR; Chen S
Pigment Cell Res; 2002 Aug; 15(4):282-9. PubMed ID: 12100494
[TBL] [Abstract][Full Text] [Related]
19. Antigenic profiles of individual-matched pairs of primary and melanoma metastases.
Meije CB; Swart GW; Lepoole C; Das PK; Van den Oord JJ
Hum Pathol; 2009 Oct; 40(10):1399-407. PubMed ID: 19386352
[TBL] [Abstract][Full Text] [Related]
20. The protein expression of TRP-1 and galectin-1 in cutaneous malignant melanomas.
Bolander A; Agnarsdóttir M; Strömberg S; Ponten F; Hesselius P; Uhlen M; Bergqvist M
Cancer Genomics Proteomics; 2008; 5(6):293-300. PubMed ID: 19287070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
